Which medication should be started for a patient with heart failure with preserved ejection fraction, hypertension, and type 2 diabetes mellitus?

Recommended Medication for HFpEF with Hypertension and Type 2 Diabetes

Start canagliflozin (or another SGLT2 inhibitor) immediately—this is the only medication among your options with proven mortality and morbidity benefits in HFpEF, regardless of diabetes status. 1

Why Canagliflozin (Option B) is the Clear Choice

SGLT2 Inhibitors: Disease-Modifying Therapy for HFpEF

• SGLT2 inhibitors are now recommended as foundational therapy for all patients with symptomatic HFpEF (NYHA class II-IV), regardless of ejection fraction or diabetes status. 1

• In the EMPEROR-Preserved trial with empagliflozin, there was a 21% reduction (HR 0.79) in the composite outcome of cardiovascular death or heart failure hospitalization in patients with HFpEF (EF >40%), with consistent benefits in patients with and without diabetes. 1

• The DELIVER trial with dapagliflozin showed an 18% reduction (HR 0.82) in worsening heart failure and cardiovascular death in HFpEF patients. 1

• A large meta-analysis of 21,947 patients across five major trials (EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and SOLOIST-WHF) demonstrated that SGLT2 inhibitors reduce cardiovascular death, heart failure hospitalization, first hospitalization for heart failure, and all-cause mortality across the entire ejection fraction spectrum. 1

Triple Benefit in This Patient

Your patient has three conditions that SGLT2 inhibitors specifically address:

1. HFpEF: Reduces heart failure hospitalizations by 23-29% across trials 1
2. Type 2 Diabetes: Provides glycemic control (though benefits persist even without diabetes) 1
3. Hypertension: Modestly lowers blood pressure as an additional benefit 1

Why the Other Options Are Inferior

A) Amiodarone:

• No role in HFpEF management unless the patient has atrial fibrillation requiring rate/rhythm control 1
• Does not modify disease progression or reduce mortality in HFpEF 1

C) Isosorbide and Hydralazine:

• This combination is specifically indicated for heart failure with reduced ejection fraction (HFrEF), particularly in African American patients 1
• No evidence supports its use in HFpEF 1
• The 2012 ESC guidelines explicitly state that no treatment had convincingly reduced morbidity and mortality in HFpEF at that time, and this combination was never studied in this population 1

D) Valsartan (ARB):

• The CHARM-Preserved trial with candesartan showed no reduction in the primary composite endpoint of cardiovascular death or heart failure hospitalization in HFpEF 1
• The I-Preserve trial with irbesartan similarly showed no reduction in death or cardiovascular hospitalization 1
• While ARBs may help control hypertension, they lack the disease-modifying benefits of SGLT2 inhibitors in HFpEF 1

Additional Management Considerations

Concurrent Therapies to Consider

• Diuretics (loop diuretics): Use judiciously to control congestion and relieve breathlessness/edema, but avoid over-diuresis which can reduce cardiac output in HFpEF 1

• Mineralocorticoid receptor antagonists (spironolactone): The TOPCAT trial showed borderline benefit (HR 0.89, not statistically significant for primary endpoint), but may be considered as adjunctive therapy 1

• Blood pressure control: Adequate treatment of hypertension is important in HFpEF management, and SGLT2 inhibitors contribute to this goal 1

Dosing and Monitoring

• Canagliflozin: Start 100 mg daily; can increase to 300 mg if tolerated and eGFR permits 1
• Monitor for genital mycotic infections, volume depletion, and rare diabetic ketoacidosis (2.2 events per 1,000 patient-years) 1
• Glycemic benefits diminish at eGFR <45 mL/min/1.73 m², but cardiovascular and renal benefits persist down to eGFR 20 mL/min/1.73 m² 1

Common Pitfalls to Avoid

• Do not withhold SGLT2 inhibitors based on diabetes status—the heart failure benefits are independent of glycemic effects 1, 2
• Do not use thiazolidinediones or certain DPP-4 inhibitors (saxagliptin, alogliptin) in patients with heart failure, as they increase heart failure risk 3
• Avoid excessive diuresis in HFpEF, which can worsen symptoms due to reduced preload dependence 1